(Q46135004)

19 December 2017

title

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer (English)

1 reference

19 December 2017

0 references

1 reference

1 reference

1

Bradley J Monk

1 reference

19 December 2017

author name string

Ernest Han

2

1 reference

19 December 2017

Carol A Josephs-Cowan

3

1 reference

19 December 2017

Gordon Pugmire

4

1 reference

19 December 2017

Robert A Burger

5

1 reference

19 December 2017

language of work or name

English

0 references

publication date

21 June 2006

1 reference

19 December 2017

published in

Gynecologic Oncology

1 reference

19 December 2017

volume

102

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

140-144

1 reference

19 December 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.05.006

10.1016/J.YGYNO.2006.05.006

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017